6.040SEK-0.66%Mkt Cap: 2.79B SEKP/E: —Last update: 2026-06-01
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for t…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.79B SEK
Enterprise Value2.34B SEK
Revenue (TTM)63.10M SEK
Gross Profit12.40M SEK
Net Income (TTM)-342.50M SEK
Revenue/Share0.1670 SEK
Last Price6.040 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)50.67
PEG—
EV/EBITDA-6.67
EV/Revenue37.01
P/S44.50
P/B9.67
EPS (TTM)-0.90
EPS (Forward)0.12
52W Range
3.03574% of range7.070
52W High7.070 SEK
52W Low3.035 SEK
Profitability
Gross Margin19.87%
Oper. Margin-693.28%
EBITDA Margin0.00%
Profit Margin-548.88%
ROE-101.15%
ROA-53.59%
Growth
Revenue Growth5.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-267.00M SEK
CapEx (TTM)1.50M SEK
FCF Margin-201.23%
FCF Yield-4.55%
Net Debt-67.30M SEK
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity0.27
Current Ratio0.69
Quick Ratio0.65
Book Value/Sh0.6290 SEK
Cash/Share0.3610 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)8.200 SEK
Target Range1.600 SEK – 12.00 SEK
# Analysts3
Ownership
Shares Out.461.83M
Float247.38M
Insiders23.23%
Institutions33.96%
Technical
SMA 505.956 (+1.4%)
SMA 2005.408 (+11.7%)
Beta0.76
S&P 52W Chg27.70%
Avg Vol (30d)988.00K
Avg Vol (10d)926.52K
Technical Indicators
RSI (14)45.3
MACD0.0684
MACD Signal0.1755
MACD Hist.-0.1072
BB Upper7.078 SEK
BB Middle6.420 SEK
BB Lower5.762 SEK
BB Width20.48%
ATR (14)0.3017 SEK
Vol Ratio (20d)1.19x